What’s New

Latest News

Liver Tumor Ablation
First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
07/14/2026
Laura Simson, MA
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high...
07/14/2026
Vascular Disease Management
Vascular Disease Management
FDA Approval
FDA Approves Gedatolisib Plus Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer
07/14/2026
Stephanie Holland
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for adults with PIK3CA wild-type HR-positive, HER2-negative locally advanced or metastatic breast cancer after endocrine therapy progression based on...
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for adults with PIK3CA wild-type HR-positive, HER2-negative locally advanced or metastatic breast cancer after endocrine therapy progression based on...
The FDA approved gedatolisib in...
07/14/2026
Oncology
Oncology
handing over the keys
News
From Drawing to Delivery: Wright Industries Presents Rescue Star Ambulance to A-Tec Ambulance
07/14/2026
Selected from hundreds of entries submitted during the show, A-Tec Ambulance won Wright Industries' exclusive EMS World Expo 2025 giveaway.
Selected from hundreds of entries submitted during the show, A-Tec Ambulance won Wright Industries' exclusive EMS World Expo 2025 giveaway.
Selected from hundreds of...
07/14/2026
EMSWorld
EMSWorld
News
The VA and HHS Partner to Improve Clinical Research on Psychedelic Drugs
07/14/2026
Rebecca Amrick
The US Department of Veterans Affairs (VA) and Department of Health and Human Services (HHS) have established a partnership designed to improve clinical trials that assess the impact of psychedelic drugs on veterans with mental illness.
The US Department of Veterans Affairs (VA) and Department of Health and Human Services (HHS) have established a partnership designed to improve clinical trials that assess the impact of psychedelic drugs on veterans with mental illness.
The US Department of Veterans...
07/14/2026
Veterans Health Today
Veterans Health Today
News
JAK Inhibitors Demonstrate Improved Efficacy but Worse Toxicity in Myelofibrosis
07/13/2026
Rebecca Amrick
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase...
07/13/2026
Journal of Clinical Pathways
Journal of Clinical Pathways
News
Osimertinib Demonstrates a Manageable Safety Profile Among Patients With NSCLC After Definitive CRT
07/13/2026
Rebecca Amrick
In the phase 3 LAURA clinical trial, osimertinib demonstrated a tolerable safety profile when used to treat patients with non–small cell lung cancer (NSCLC) after definitive chemoradiotherapy (CRT).
In the phase 3 LAURA clinical trial, osimertinib demonstrated a tolerable safety profile when used to treat patients with non–small cell lung cancer (NSCLC) after definitive chemoradiotherapy (CRT).
In the phase 3 LAURA clinical...
07/13/2026
First Report Managed Care
First Report Managed Care
a hand points to a specific spot on a brain scan
News
P2Y12 Inhibitors Linked to Worse Intracerebral Hemorrhage Outcomes in Nationwide Study
07/13/2026
Maria Mantas
A nationwide cohort study found that prior use of P2Y12 inhibitors, either alone or combined with aspirin, was associated with more severe presentation and worse hospital outcomes in patients with spontaneous ICH.
A nationwide cohort study found that prior use of P2Y12 inhibitors, either alone or combined with aspirin, was associated with more severe presentation and worse hospital outcomes in patients with spontaneous ICH.
A nationwide cohort study found...
07/13/2026
Neurology
Neurology

Latest Research

Journal of Clinical Pathways logo
Journal of Clinical Pathways
Building Better Oncology Pathways With Specialty Pharmacy Integration
Vol. 12, Issue 3, Issue July 2026
First Report Managed Care
First Report Managed Care
Congress Shifts Focus as Health Policy Scrutiny Continues
Vol. 23, Issue 2, Issue July 2026

HMP Global Learning Network

Featured Interviews

Edgardo Santos, MD
Videos
When Standard Therapy Is Not Feasible in Stage III Non–Small Cell Lung Cancer
06/30/2026
Edgardo Santos, MD
Edgardo Santos, MD, reviews the clinical decision-making behind the management of a patient with unresectable stage III KRAS G12C–mutated, PD-L1–high non–small cell lung cancer, highlighting the roles of molecular profiling, radiation...
Edgardo Santos, MD, reviews the clinical decision-making behind the management of a patient with unresectable stage III KRAS G12C–mutated, PD-L1–high non–small cell lung cancer, highlighting the roles of molecular profiling, radiation...
Edgardo Santos, MD, reviews the...
06/30/2026
Oncology
Part 5 panel
Videos
Safety Monitoring in High-Risk CSCC
06/24/2026
Christopher Barker, MD; Krupal Patel, MD, MSc, FRCSC, FACS; John Strasswimmer, MD, PhD, FAAD, FACMS; Deborah J.L. Wong, MD, PhD
The roundtable discussion concludes with a review of the safety profile of adjuvant cemiplimab and best practices for monitoring and managing adverse events in patients with high-risk CSCC, with an emphasis on multidisciplinary follow-up,...
The roundtable discussion concludes with a review of the safety profile of adjuvant cemiplimab and best practices for monitoring and managing adverse events in patients with high-risk CSCC, with an emphasis on multidisciplinary follow-up,...
The roundtable discussion...
06/24/2026
The Dermatologist
Pediatric Video Tutorial: The Future of 'Color Coding' Kids
Videos
Pediatric Video Tutorial: The Future of 'Color Coding' Kids
06/19/2026
Scott DeBoer, RN, MSN, CPEN, CEN, CCRN, CFRN
Variations of the Broselow tape have been in use for almost 40 years. Variations of Handtevy have been in use for over 15 years. Let’s use our crystal ball to gaze into the very near future of color coding kids.
Variations of the Broselow tape have been in use for almost 40 years. Variations of Handtevy have been in use for over 15 years. Let’s use our crystal ball to gaze into the very near future of color coding kids.
Variations of the Broselow tape...
06/19/2026
EMSWorld
Bruce Sands
Expert Insights
Bruce Sands, MD, on Results from DUET-CD
05/19/2026
Bruce E. Sands, MD, MS
Dr Sands reviews the results of the DUET-CD study of combination therapy with guselkumab and golimumab in patients with Crohn's disease, which showed a significant increase in efficacy for the combination versus either drug independently.
Dr Sands reviews the results of the DUET-CD study of combination therapy with guselkumab and golimumab in patients with Crohn's disease, which showed a significant increase in efficacy for the combination versus either drug independently.
Dr Sands reviews the results of...
05/19/2026
Advances in Inflammatory Bowel Disease Network
pediatric asthma
Videos
Pediatric Video Tutorial: Pediatric Asthma
05/19/2026
Scott DeBoer, RN, MSN, CPEN, CEN, CCRN, CFRN
Listening for wheezing is good, but asking two simple questions and listening to them talk can be even better.
Listening for wheezing is good, but asking two simple questions and listening to them talk can be even better.
Listening for wheezing is good,...
05/19/2026
EMSWorld
CTP News Desk Image
Viewpoints
Skin Substitute Reimbursement Changes 2026: MAC Denials, Q Codes, and What’s Next
05/19/2026
Daniel L. Kapp, MD
Daniel Kapp, MD, shares his observations on conflicting Medicare contractor guidance and coding confusion in early 2026 have effectively halting reimbursement for skin substitute applications in one MAC. 
Daniel Kapp, MD, shares his observations on conflicting Medicare contractor guidance and coding confusion in early 2026 have effectively halting reimbursement for skin substitute applications in one MAC. 
Daniel Kapp, MD, shares his...
05/19/2026
Wounds
CTP News Desk Image
Viewpoint
Operational Observations in a New CTP Regulatory Environment
05/08/2026
Nikki Johnston; Kati Kaushal, DNP, FNP-C, CWS
Learn more about these consultants' observations in this new regulatory environment.
Learn more about these consultants' observations in this new regulatory environment.
Learn more about these...
05/08/2026
Wounds
Advances in Charcot Neuroarthropathy Surgical Techniques Video
Videos
Advances in Charcot Neuroarthropathy Surgical Techniques Video
05/01/2026
Zeeshan S. Husain, DPM, FACFAS, FASPS; Athanasios Garbis, DPM; Kyle Lawton, DPM
In this video, we highlight emerging reconstruction strategies that move beyond traditional rigid fixation toward a more functional approach to limb preservation.
In this video, we highlight emerging reconstruction strategies that move beyond traditional rigid fixation toward a more functional approach to limb preservation.
In this video, we highlight...
05/01/2026
Podiatry Today
Jonathan Friedberg, MD
Videos
Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine in Advanced Hodgkin Lymphoma
04/30/2026
Jonathan W. Friedberg, MD, MMSc
Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.
Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.
Jonathan Friedberg, MD, MMSc,...
04/30/2026
Oncology
Advanced Squamous Cell Carcinoma of the Anal Canal
Videos
Evaluating Retifanlimab for Advanced Squamous Cell Carcinoma of the Anal Canal in the Frontline Setting
03/31/2026
Lingbin Meng, MD, PhD
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how...
03/31/2026
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use